Go Pro
→ Elon Musk’s Hushed FCC Filing. Sept 25th. (From Paradigm Press) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
$53.01
$47.81
$29.43
▼
$90.32
$2.76B-2.221.75 million shsN/A
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
0.00%0.00%0.00%0.00%-24.50%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
$53.01
$47.81
$29.43
▼
$90.32
$2.76B-2.221.75 million shsN/A
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
0.00%0.00%0.00%0.00%-24.50%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
2.00
Hold$73.0037.71% Upside

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
$285.01M9.69$0.43 per share124.10$9.51 per share5.57
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
$20.89M$1.7729.959.89N/A33.70%22.85%18.25%N/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
0.10
5.62
5.32

Institutional Ownership

CompanyInstitutional Ownership
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
97.42%

Insider Ownership

CompanyInsider Ownership
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
6.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
3052.12 million48.78 millionOptionable

Recent News About These Companies

Kuehn Law Encourages Investors of Soleno Therapeutics, Inc. to Contact Law Firm
September 2, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/kuehn-law-encourages-investors-of-soleno-therapeutics-inc-to-contact-law-firm-302867880.html
SLNO 8-DAY DEADLINE ALERT: Hagens Berman Alerts Soleno Therapeutics (SLNO) Investors to Securities Class Action Alleging Hyperphagia Drug Launch Disruptions - Hagens Berman
May 11, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/slno-8-day-deadline-alert-hagens-berman-alerts-soleno-therapeutics-slno-investors-to-securities-class-action-alleging-hyperphagia-drug-launch-disruptions--hagens-berman-302761294.html
Soleno Merger With Neurocrine Puts Profitability And Valuation In Focus
May 10, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/soleno-merger-neurocrine-puts-profitability-031409782.html
SOLENO DEADLINE TODAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SLNO
May 5, 2026  |  newsfilecorp.comN
SOLENO DEADLINE TODAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SLNO
May 5, 2026  |  newsfilecorp.comN
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Soleno Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – SLNO
May 5, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/05/3288378/1087/en/investor-alert-pomerantz-law-firm-reminds-investors-with-losses-on-their-investment-in-soleno-therapeutics-inc-of-class-action-lawsuit-and-upcoming-deadlines-slno.html
SLNO DEADLINE ALERT: Hagens Berman Alerts Soleno Therapeutics (SLNO) Investors to Today's Lead Plaintiff Deadline in Securities Class Action
May 5, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/slno-deadline-alert-hagens-berman-alerts-soleno-therapeutics-slno-investors-to-todays-lead-plaintiff-deadline-in-securities-class-action-302762934.html
DEADLINE ALERT for EOSE, SLNO, and NKTR: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
May 5, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/05/3288013/0/en/deadline-alert-for-eose-slno-and-nktr-the-law-offices-of-frank-r-cruz-reminds-investors-of-class-actions-on-behalf-of-shareholders.html
SLNO Shareholder Alert: Soleno Therapeutics, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact The Gross Law Firm
May 5, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/slno-shareholder-alert-soleno-therapeutics-inc-securities-class-action-lawsuit---investors-with-losses-may-contact-the-gross-law-firm-302762256.html
Portnoy Law Firm Announces Class Action on Behalf of Soleno Therapeutics, Inc. Investors
May 5, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/05/3287722/0/en/portnoy-law-firm-announces-class-action-on-behalf-of-soleno-therapeutics-inc-investors.html
SOLENO THERAPEUTICS DEADLINE TOMORROW: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SLNO
May 4, 2026  |  newsfilecorp.comN
SOLENO THERAPEUTICS CLASS ACTION DEADLINE TOMORROW: Bragar Eagel & Squire, P.C. Urges Soleno Therapeutics, Inc. Investors with Significant Losses to Contact the Firm Before May 5th Lead Plaintiff Deadline
May 4, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/04/3287238/0/en/soleno-therapeutics-class-action-deadline-tomorrow-bragar-eagel-squire-p-c-urges-soleno-therapeutics-inc-investors-with-significant-losses-to-contact-the-firm-before-may-5th-lead-p.html
Deadline Soon: Soleno Therapeutics, Inc. (SLNO) Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
May 4, 2026  |  tmcnet.comhttps://www.tmcnet.com/usubmit/2026/05/04/10376148.htm
SOLENO THERAPEUTICS DEADLINE TOMORROW: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SLNO
May 4, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/04/3287004/673/en/soleno-therapeutics-deadline-tomorrow-rosen-global-investor-counsel-encourages-soleno-therapeutics-inc-investors-to-secure-counsel-before-important-deadline-in-securities-class-act.html
SLNO INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Soleno Therapeutics (SLNO) Investors of Securities Class Action Deadline on May 5, 2026
May 4, 2026  |  newsfilecorp.comN
Bronstein, Gewirtz & Grossman LLC Urges Soleno Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
May 4, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/04/3286971/9788/en/bronstein-gewirtz-grossman-llc-urges-soleno-therapeutics-inc-investors-to-act-class-action-filed-alleging-investor-harm.html
SLNO Deadline: SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud Lawsuit
May 4, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/slno-deadline-slno-investors-have-opportunity-to-lead-soleno-therapeutics-inc-securities-fraud-lawsuit-302760731.html
SLNO SHAREHOLDER NOTICE: Hagens Berman Alerts Soleno (SLNO) Investors to Pending Securities Fraud Class Action and Upcoming May 5th Lead Plaintiff Deadline
May 4, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/04/3286725/32716/en/slno-shareholder-notice-hagens-berman-alerts-soleno-slno-investors-to-pending-securities-fraud-class-action-and-upcoming-may-5th-lead-plaintiff-deadline.html
Soleno Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SLNO
May 4, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/soleno-therapeutics-inc-sued-for-securities-law-violations---contact-the-djs-law-group-to-discuss-your-rights--slno-302760950.html
SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
May 4, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/slno-investors-have-opportunity-to-lead-soleno-therapeutics-inc-securities-fraud-lawsuit-with-the-schall-law-firm-302760933.html
Soleno Therapeutics stock logo

Soleno Therapeutics NASDAQ:SLNO

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas